Share-based Payment Arrangement, Expense of Dianthus Therapeutics, Inc. /DE/ from 31 Dec 2016 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Dianthus Therapeutics, Inc. /DE/ quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Dec 2016 to 30 Sep 2025.
  • Dianthus Therapeutics, Inc. /DE/ Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $5,794,000, a 51% increase year-over-year.
  • Dianthus Therapeutics, Inc. /DE/ Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $20,733,000, a 114% increase year-over-year.
  • Dianthus Therapeutics, Inc. /DE/ annual Share-based Payment Arrangement, Expense for 2024 was $12,894,000, a 345% increase from 2023.
  • Dianthus Therapeutics, Inc. /DE/ annual Share-based Payment Arrangement, Expense for 2023 was $2,900,000, a 91% increase from 2022.
  • Dianthus Therapeutics, Inc. /DE/ annual Share-based Payment Arrangement, Expense for 2022 was $1,518,000, a 2310% increase from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Dianthus Therapeutics, Inc. /DE/ Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $20,733,000 $5,794,000 +$1,954,000 +51% 01 Jul 2025 30 Sep 2025 10-Q 05 Nov 2025 2025 Q3
Q2 2025 $18,779,000 $5,706,000 +$2,605,000 +84% 01 Apr 2025 30 Jun 2025 10-Q 07 Aug 2025 2025 Q2
Q1 2025 $16,174,000 $5,315,000 +$3,280,000 +161% 01 Jan 2025 31 Mar 2025 10-Q 12 May 2025 2025 Q1
Q4 2024 $12,894,000 $3,918,000 +$3,192,000 +440% 01 Oct 2024 31 Dec 2024 10-K 11 Mar 2025 2024 FY
Q3 2024 $9,702,000 $3,840,000 +$2,661,000 +226% 01 Jul 2024 30 Sep 2024 10-Q 05 Nov 2025 2025 Q3
Q2 2024 $7,041,000 $3,101,000 +$2,639,000 +571% 01 Apr 2024 30 Jun 2024 10-Q 07 Aug 2025 2025 Q2
Q1 2024 $4,402,000 $2,035,000 +$1,502,000 +282% 01 Jan 2024 31 Mar 2024 10-Q 12 May 2025 2025 Q1
Q4 2023 $2,900,000 $726,000 +$3,619,000 01 Oct 2023 31 Dec 2023 10-K 11 Mar 2025 2024 FY
Q3 2023 $719,000 $1,179,000 +$518,000 +78% 01 Jul 2023 30 Sep 2023 10-Q 07 Nov 2024 2024 Q3
Q2 2023 $1,237,000 $462,000 -$1,383,000 -75% 01 Apr 2023 30 Jun 2023 10-Q 08 Aug 2024 2024 Q2
Q1 2023 $146,000 $533,000 -$1,372,000 -72% 01 Jan 2023 31 Mar 2023 10-Q 09 May 2024 2024 Q1
Q4 2022 $1,518,000 $2,893,000 +$5,169,000 +64% 01 Oct 2022 31 Dec 2022 10-K 21 Mar 2024 2023 FY
Q3 2022 $3,651,000 $661,000 -$3,138,000 -83% 01 Jul 2022 30 Sep 2022 10-Q 09 Nov 2023 2023 Q3
Q2 2022 $513,000 $1,845,000 -$289,000 -14% 01 Apr 2022 30 Jun 2022 10-Q 03 Aug 2023 2023 Q2
Q1 2022 $224,000 $1,905,000 -$287,000 -13% 01 Jan 2022 31 Mar 2022 10-Q 15 May 2023 2023 Q1
Q4 2021 $63,000 $8,062,000 -$10,393,000 -446% 01 Oct 2021 31 Dec 2021 8-K 21 Dec 2023
Q3 2021 $10,456,000 $3,799,000 +$1,433,000 +61% 01 Jul 2021 30 Sep 2021 10-Q 03 Nov 2022 2022 Q3
Q2 2021 $9,023,000 $2,134,000 -$370,000 -15% 01 Apr 2021 30 Jun 2021 10-Q 04 Aug 2022 2022 Q2
Q1 2021 $9,393,000 $2,192,000 -$548,000 -20% 01 Jan 2021 31 Mar 2021 10-Q 16 May 2022 2022 Q1
Q4 2020 $9,941,000 $2,331,000 +$269,000 +13% 01 Oct 2020 31 Dec 2020 10-K 08 Mar 2022 2021 FY
Q3 2020 $9,672,000 $2,366,000 -$396,000 -14% 01 Jul 2020 30 Sep 2020 10-Q 04 Nov 2021 2021 Q3
Q2 2020 $10,068,000 $2,504,000 -$96,000 -3.7% 01 Apr 2020 30 Jun 2020 10-Q 05 Aug 2021 2021 Q2
Q1 2020 $10,164,000 $2,740,000 +$163,000 +6.3% 01 Jan 2020 31 Mar 2020 10-Q 06 May 2021 2021 Q1
Q4 2019 $10,001,000 $2,062,000 -$489,000 -19% 01 Oct 2019 31 Dec 2019 10-K 03 Mar 2021 2020 FY
Q3 2019 $10,490,000 $2,762,000 -$914,000 -25% 01 Jul 2019 30 Sep 2019 10-Q 05 Nov 2020 2020 Q3
Q2 2019 $11,404,000 $2,600,000 -$451,000 -15% 01 Apr 2019 30 Jun 2019 10-Q 06 Aug 2020 2020 Q2
Q1 2019 $11,855,000 $2,577,000 +$1,152,000 +81% 01 Jan 2019 31 Mar 2019 10-Q 07 May 2020 2020 Q1
Q4 2018 $10,703,000 $2,551,000 01 Oct 2018 31 Dec 2018 10-K 03 Mar 2020 2019 FY
Q3 2018 $3,676,000 +$3,111,000 +551% 01 Jul 2018 30 Sep 2018 10-Q 13 Nov 2019 2019 Q3
Q2 2018 $3,051,000 +$2,444,000 +403% 01 Apr 2018 30 Jun 2018 10-Q 08 Aug 2019 2019 Q2
Q1 2018 $1,425,000 01 Jan 2018 31 Mar 2018 10-Q 09 May 2019 2019 Q1
Q3 2017 $565,000 01 Jul 2017 30 Sep 2017 10-Q 08 Nov 2018 2018 Q3
Q2 2017 $607,000 01 Apr 2017 30 Jun 2017 10-Q 09 Aug 2018 2018 Q2

Dianthus Therapeutics, Inc. /DE/ Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $12,894,000 +$9,994,000 +345% 01 Jan 2024 31 Dec 2024 10-K 11 Mar 2025 2024 FY
2023 $2,900,000 +$1,382,000 +91% 01 Jan 2023 31 Dec 2023 10-K 11 Mar 2025 2024 FY
2022 $1,518,000 +$1,455,000 +2310% 01 Jan 2022 31 Dec 2022 10-K 21 Mar 2024 2023 FY
2021 $63,000 -$9,878,000 -99% 01 Jan 2021 31 Dec 2021 8-K 21 Dec 2023
2020 $9,941,000 -$60,000 -0.6% 01 Jan 2020 31 Dec 2020 10-K 08 Mar 2022 2021 FY
2019 $10,001,000 -$702,000 -6.6% 01 Jan 2019 31 Dec 2019 10-K 03 Mar 2021 2020 FY
2018 $10,703,000 +$8,444,000 +374% 01 Jan 2018 31 Dec 2018 10-K 03 Mar 2020 2019 FY
2017 $2,259,000 +$1,597,000 +241% 01 Jan 2017 31 Dec 2017 10-K 03 Mar 2020 2019 FY
2016 $662,000 01 Jan 2016 31 Dec 2016 10-K 19 Mar 2019 2018 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.